Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1007

Shown on this page

Current sort

Live official records

Conditions: Lung Neoplasms
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2035
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
Interventions: Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 3 Years to 39 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Peripheral Nerve Injuries
Interventions: Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization; Other · Device · Procedure
Lead sponsor: Axogen Corporation; Industry
Eligibility: Not listed
Enrollment: 3,126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 46
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 33 more

Conditions: Non Small Cell Lung Cancer, Breast Cancer
Interventions: Abemaciclib, Pembrolizumab, Anastrozole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Back Pain, Neck Pain
Interventions: THC/CBD, THC, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 84 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperlipidemia
Interventions: Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider; Other
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Spinal Fusion, Deformity of Spine
Interventions: iFuse Bedrock Granite Implant System; Device
Lead sponsor: SI-BONE, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Mobile, Alabama • Aurora, Colorado • Royal Oak, Michigan + 6 more

Conditions: Brain and Central Nervous System Tumors
Interventions: concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2029
U.S. locations: 271
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more

Conditions: Pregnancy Outcome Trends in Low-resource Geographic Areas
Interventions: There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.; Other
Lead sponsor: NICHD Global Network for Women's and Children's Health; Network
Eligibility: Not listed
Enrollment: 950,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
Interventions: Venetoclax, Azacitidine, Mitoxantrone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: AML
Interventions: Venetoclax, CC-486; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: [Lu-177]-PNT2002, Abiraterone, Enzalutamide; Drug
Lead sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 33
States / cities: Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more

About this University of Colorado Anschutz institution page

What this page lists: ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Colorado Anschutz

Filter and sort this campus

Live official records

Specimen Banking From Patients With Lung Cancer

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Safety and Efficacy of Oral Cannabis in Chronic Spine Pain

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

Pelvic Fixation and Fusion During Multilevel Spinal Surgery

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Maternal Newborn Health Registry

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

CC-486 and Venetoclax for Acute Myeloid Leukemia

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

About this University of Colorado Anschutz institution page